Abstract
Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have